Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Vaxcyte, Inc.

Get SEC filing alerts via email and in your feed for Vaxcyte, Inc.

PCVX

Vaxcyte, Inc.

About Vaxcyte, Inc.

Vaxcyte, Inc. is a vaccine innovation company developing broad-spectrum conjugate and protein vaccines targeting bacterial infectious diseases. Utilizing advanced synthetic chemistry and cell-free protein synthesis platforms, it focuses on pneumococcal, Group A Streptococcus, periodontitis, and shigellosis vaccines for adult and pediatric markets. Its core value lies in creating highly immunogenic, scalable, and next-generation vaccines to address unmet medical needs and improve global health.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Vaxcyte, Inc.

1
1
Vaxcyte, Inc. Vaxcyte Reports $320.6 Million Net Loss and Expands Clinical Programs in Latest 10-Q Filing

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Vaxcyte, Inc. Vaxcyte Reports $766.6 Million Net Loss for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Vaxcyte, Inc. Vaxcyte Reports $212.8 Million Net Loss in Q3 2025, Plans Phase 3 Trials for Vaccine Candidates

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Vaxcyte, Inc. Vaxcyte Reports $166.6 Million Net Loss in Q2 2025, Increases R&D Spending

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Vaxcyte, Inc. Vaxcyte Reports $140.7 Million Net Loss in Q1 2025, Increases R&D Spending

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Vaxcyte, Inc. Vaxcyte Reports Significant Cash Reserves Growth, Net Losses Continue Amid Rising Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments